Gregorio Mara News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

Patients with microscopic plastics in their arteries multiply their risk of myocardial infarction, stroke and death by 4.5

An oncological experimental applied therapy, thanks to the CRIS Foundation, brought about remission in the case of a seven-year-old boy whose alternative was palliative care

(2024-02-14 | NDAQ:GLSI) Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Harvey Sultzer, the husband of the late Sandra Sultzer, filed a lawsuit on Feb. 6 against Intuitive Surgical (IS) claiming his wife suffered health complications following a procedure completed by their surgical robot.